This suggests that targeting SIRT7 could synergistically enhance the effectiveness of established chemotherapeutic regimens, providing a viable strategy for addressing the challenges posed by treatment-resistant PCa. The gene discussed is SIRT7; the disease is posterior cortical atrophy.